BACKGROUND Studies have shown that patients with chronic renal failure(CRF)are more likely to suffer from breast cancer and other malignant tumors.To our knowledge,CRF can reduce drug excretion,thereby increase drug e...BACKGROUND Studies have shown that patients with chronic renal failure(CRF)are more likely to suffer from breast cancer and other malignant tumors.To our knowledge,CRF can reduce drug excretion,thereby increase drug exposure and lead to increased toxicity,which will limit drug treatment and lead to tumor progression.Currently,there are few successful reports on the combination of docetaxel,trastuzumab,and pertuzumab(THP)as a neoadjuvant treatment regimen for breast cancer patients with CRF.CASE SUMMARY We report a breast cancer(cT2N2M0,Her-2+/HR-)patient with CRF.It was a clinical stage IIIA tumor on the left breast.The patient had suffered from uremia for 2 years,and her heart function was normal.Based on the pathological type,molecular type,and clinical stage of breast cancer,and the patient’s renal function,the clinician analyzed the pharmacological and pharmacokinetic characteristics of the antitumor drugs after consulting the relevant literature,and prescribed the neoadjuvant regimen of THP(docetaxel 80 mg/m²,trastuzumab 8 mg/kg for the first dose,and 6 mg/kg for the maintenance dose with pertuzumab 840 mg for the first dose and 420 mg for the maintenance dose),once every 3 wk,for a total of 6 courses.The neoadjuvant treatment had a good effect,and the patient then underwent surgery which was uneventful.CONCLUSION CRF is not a contraindication for systemic treatment and surgery of breast cancer.The THP regimen without dose adjustment may be a safe and effective neoadjuvant treatment for HER-2 positive breast cancer patients with CRF.展开更多
To seek an effective treatment to delay the development of chronic renal failure, the au-thors studied the effects of a therapy integrating Chinese and Western medicine with rhubarb as the maindrug. Sixty hospitalized...To seek an effective treatment to delay the development of chronic renal failure, the au-thors studied the effects of a therapy integrating Chinese and Western medicine with rhubarb as the maindrug. Sixty hospitalized patients were divided into an integrated Chinese and Western medicine therapygroup (test group, 30 cases) and a Western therapy group (control group, 30 cases) . There were no dif-ferences in age, sex, underlying diseases and renal function of the two groups. The patients in bothgroups were treated for three weeks as a therapy course. The results show the levels of blood urea nitro-gen and serum creatinine after treatment were higher than before treatment in the control group, but lowerin the test group. The value of reciprocal coefficient (slope or b value) relationship between inverseserum creatinine slope and time in the control group was -1.198 3. 931, but the slope(b value) in thetest group was 0. 125 2. 252. There were no side-effects to be found in either group. The study suggeststhat integrated Chinese and Western medicine using rhubarb as a main drug can delay renal function dete-rioration and improve renal function in some cases.展开更多
文摘BACKGROUND Studies have shown that patients with chronic renal failure(CRF)are more likely to suffer from breast cancer and other malignant tumors.To our knowledge,CRF can reduce drug excretion,thereby increase drug exposure and lead to increased toxicity,which will limit drug treatment and lead to tumor progression.Currently,there are few successful reports on the combination of docetaxel,trastuzumab,and pertuzumab(THP)as a neoadjuvant treatment regimen for breast cancer patients with CRF.CASE SUMMARY We report a breast cancer(cT2N2M0,Her-2+/HR-)patient with CRF.It was a clinical stage IIIA tumor on the left breast.The patient had suffered from uremia for 2 years,and her heart function was normal.Based on the pathological type,molecular type,and clinical stage of breast cancer,and the patient’s renal function,the clinician analyzed the pharmacological and pharmacokinetic characteristics of the antitumor drugs after consulting the relevant literature,and prescribed the neoadjuvant regimen of THP(docetaxel 80 mg/m²,trastuzumab 8 mg/kg for the first dose,and 6 mg/kg for the maintenance dose with pertuzumab 840 mg for the first dose and 420 mg for the maintenance dose),once every 3 wk,for a total of 6 courses.The neoadjuvant treatment had a good effect,and the patient then underwent surgery which was uneventful.CONCLUSION CRF is not a contraindication for systemic treatment and surgery of breast cancer.The THP regimen without dose adjustment may be a safe and effective neoadjuvant treatment for HER-2 positive breast cancer patients with CRF.
文摘To seek an effective treatment to delay the development of chronic renal failure, the au-thors studied the effects of a therapy integrating Chinese and Western medicine with rhubarb as the maindrug. Sixty hospitalized patients were divided into an integrated Chinese and Western medicine therapygroup (test group, 30 cases) and a Western therapy group (control group, 30 cases) . There were no dif-ferences in age, sex, underlying diseases and renal function of the two groups. The patients in bothgroups were treated for three weeks as a therapy course. The results show the levels of blood urea nitro-gen and serum creatinine after treatment were higher than before treatment in the control group, but lowerin the test group. The value of reciprocal coefficient (slope or b value) relationship between inverseserum creatinine slope and time in the control group was -1.198 3. 931, but the slope(b value) in thetest group was 0. 125 2. 252. There were no side-effects to be found in either group. The study suggeststhat integrated Chinese and Western medicine using rhubarb as a main drug can delay renal function dete-rioration and improve renal function in some cases.
